目的 初步探讨泰它西普治疗儿童IgA肾病的有效性和安全性。 方法 回顾性收集2024年1月—2025年10月于福州大学附属省立医院儿科接受泰它西普治疗的11例IgA肾病患儿临床资料，比较治疗前后24 h尿蛋白、血清白蛋白、免疫球蛋白（IgG、IgA、IgM）、外周血CD19⁺细胞、估算肾小球滤过率（estimated glomerular filtration rate, eGFR）、糖皮质激素剂量等指标变化，记录不良反应。 结果 治疗后4、12、24、36、48周，24 h尿蛋白定量均较基线显著降低（P<0.05），12周时降幅达最大（P<0.001）；血清白蛋白较基线升高，12、24、36周差异有统计学意义（P<0.05）。IgG、IgA在各时间点均显著下降（P<0.05），IgM整体呈下降趋势（P<0.05）；CD19⁺细胞计数无明显变化（P>0.05）。糖皮质激素剂量显著减少（P<0.05），eGFR无显著改变（P>0.05）。不良反应共6例次，以轻度呼吸道感染为主，未见严重不良事件。 结论 泰它西普可有效降低IgA肾病患儿的蛋白尿水平，整体安全性良好。

Objective To preliminarily assess the efficacy and safety of telitacicept in pediatric IgA nephropathy (IgAN). Methods Clinical data of 11 children with IgAN who received telitacicept in the Department of Pediatrics, Provincial Hospital Affiliated to Fuzhou University, from January 2024 to October 2025 were retrospectively collected. Parameters compared before and after treatment included 24-hour urinary protein, serum albumin, immunoglobulins (IgG, IgA, IgM), peripheral blood CD19⁺ cells, estimated glomerular filtration rate (eGFR), and glucocorticoid dosage. Adverse events were recorded. Results At 4, 12, 24, 36, and 48 weeks after treatment, 24-hour urinary protein was significantly lower than baseline (all P<0.05), with the greatest reduction at 12 weeks (P<0.001). Serum albumin increased compared with baseline, reaching statistical significance at 12, 24, and 36 weeks (all P<0.05). IgG and IgA levels decreased significantly at all time points (all P<0.05), and IgM showed an overall downward trend (P<0.05). CD19⁺ cell counts showed no significant change (P>0.05). Glucocorticoid dosage was significantly reduced (P<0.05), while eGFR showed no significant change (P>0.05). A total of 6 adverse event episodes were recorded, predominantly mild respiratory infections; no serious adverse events occurred. Conclusions Telitacicept can effectively reduce proteinuria in children with IgAN and demonstrates an overall favorable safety profile.